Biotricity Reports Strong Q2 2025 Results, Highlighting AI-Driven Growth in Remote Cardiac Monitoring

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

, (GLOBE NEWSWIRE) -- (OTCQB: BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter of fiscal 2025 year and (unaudited) ended . Dr. Waqaas Al-Siddiq, Biotricity's Founder & CEO, said, "In the second quarter of fiscal 2025, we continued our mission to produce transformative healthcare technologies, while demonstrating our strong commitment to automation, operational efficiency and financial discipline. Our primary focus remains on driving revenue and margins, and we were pleased to see these metrics trend upwards. This quarter, we continued to leverage our data intelligently, optimizing patient outcomes through continuous development and advancement of our innovative diagnostic solutions. Our suite of products, combined with our robust platform, continues to improve in response to feedback received from cardiologists and electrophysiologists who seek to provide superior patient care. We have now recorded hundreds of billions of heartbeats as part of our Cardiac AI cloud. Over the past two years, our solutions have made a significant impact, with more than 50K atrial fibrillation (Afib) diagnoses, a leading cause of stroke . Our technology offers patients the prospect of earlier medical intervention, producing substantial healthcare savings for both patients and the healthcare system. Building on this success, has expanded our AI technology development in remote cardiac care, harnessing proprietary AI technology to develop a suite of predictive remote monitoring tools that enhance new disease profiling, improve patient management, and revolutionize disease prevention. The results for our second quarter demonstrate year-over-year revenue growth and improvements in all key operating metrics- specifically in recurring technology fees, device sales, and gross margins. Throughout this, we've maintained a strong focus on cost control and expense management, and we continue to make consistent progress towards our goal of achieving positive cash flow and profitability." Full details of the Company's financial results will be filed with the on Form 10-Q and available by visiting www.sec.gov. Financial Results and Business Update Conference Call Management will host a conference call on at to discuss its financial results for the fiscal 2025 second quarter and provide a business update. Additional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/ Event: Biotricity Second Quarter FY 2025 Financial Results and Business Update Call Date: Time: () Toll Free: 877-269-7751 International: 1-201-389-0908 Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1697705&tp_key=6ae5e1a902 Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately 3 hours after the live call via the Investors section of the website at https://www.biotricity.com/investors/. is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com. Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the . There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript

Dr. Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - Chief Financial Officer Greetings. And welcome to the Biotricity Conference Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Founder and CEO, Dr. Waqaas Al-Siddiq. Thank you. You may begin. Dr. Waqaas Al-Siddiq Thank you everybody for joining us today. Second quarter 2025 has been a transformative quarter for Biotricity marked by significant advancements and strategic initiatives that has led to us achieving positive EBITDA for the first time in September and continue our path to profitability. One of our most significant achievements this quarter has been the improvement in all aspects of the business from revenues to margins, operational efficiency and a shift to positive EBITDA. Our commitment to innovation, strategic partnerships and operational efficiency has allowed us to make remarkable progress across multiple fronts. We are continuing to expand our Cardiac AI Cloud capabilities harnessing our data to explore predictive capabilities with our platform. Recently, we published our research in predicting postoperative complications in Nature. We expect to expand our research and file for FDA of our AI clinical model by mid next year. Our recent strategic alliances with the top group purchasing organizations, otherwise known as GPOs and specialist organizations in neurology and pulmonology are beginning to gain momentum. These partnerships have helped kick off multiple large opportunities that are currently in pilots along with expanding our reach beyond cardiology, significantly expanding our market reach. This positions us to capitalize